바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.60 No.2
Citation Share

Clinical Characteristics of Intensive Care Unit Patients with Carbapenem Resistant Acinetobacter Baumannii Isolated from Sputum

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2006, v.60 no.2, pp.228-234



& (2006). Clinical Characteristics of Intensive Care Unit Patients with Carbapenem Resistant Acinetobacter Baumannii Isolated from Sputum. Tuberculosis & Respiratory Diseases, 60(2), 228-234.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background : Acinetobacter baumannii is an important pathogen associated with nosocomial infections in intensive care units, and is responsible for nosocomial pneumonia, UTI, bacteremia, etc. The main concern is that this pathogen is often resistant to many antimicrobial agents, particularly to carbapenem. This study compared the clinical those of ICU admitted patients with the carbapenem resistant A. baumannii isolated from the sputum with characteristics of patients with carbapenem sensitive A. baumannii.Methods : A total of 49 patients with A. baumannii from a sputum culture who were admitted to the ICU from January to December 2003 were enrolled in this study. This study evaluated the demographic variables, mortality, APACHE II score, comorbidity, antibiotics used, hospital and ICU stay, Clinical Pulmonary Infection Score, and mechanical ventilation. A retrospective analysis was made by a review of the patients' medical records.Results : Carbapenem sensitive and resistant A. baumannii was isolated from 23 patients and 26 patients respectively. Univariate analysis revealed renal disease, the use of carbapenem and aminoglycoside to be statistically significant factors for carbapenem resistance. Multivariate analysis revealed carbapenem use(p=0.024; OR, 8.17; CI 1.32 to 50.68) to be positively associated with carbapenem resistance, and aminoglycoside use(p=0.026; OR, 0.18; CI, 0.04 to 0.82) to be negatively associated with carbapenem resistance. There was no significant difference in mortality between the carbapenem sensitive and resistant group(30 vs 42%. P=0.39).Conclusion : The occurrence of carbapenem resistant A. baumannii is positively associated with carbapenem use and negatively associated with aminoglycoside use. Carbapenem resistance in the sputum culture did not affect the mortality rate. (Tuberc Respir Dis 2006; 60: 228-234)

keywords
Acinetobacter baumannii, Drug resistance, Carbapenem, Acinetobacter baumannii, Drug resistance, Carbapenem

Reference

1.

(2004) Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an Intensive Care Unit shows the emergence of carbapenem resistance,

2.

(2003) Multiresistant Acinetobacter baumannii isolates in intensive care units in Greece,

3.

(2002) Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment,

4.

(2004) Antimicrobial resistance of Acinetobacter spp. in Europe,

5.

(2004) In Vitro Activities of the β-Lactamase Inhibitors Clavulanic Acid and Tazobactam Alone or in Combination with β-Lactams against Epidemiologically Characterized Multidrug-Resistant Acinetobacter baumannii Strains,

6.

(2003) The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000,

7.

(2004) Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii,

8.

(2002) Multiresistant Acinetobacter infections:a role for sulbactam combinations in overcoming an emerging worldwide problem,

9.

(2000) Emergence and Rapid Spread of Carbapenem Resistance during a Large and Sustained Hospital Outbreak of Multiresistant Acinetobacter baumannii,

10.

(1985) APACHE II:A severity of disease classification system,

11.

(2003) Clinical usefulness of ClinicalPulmonary Infection Score of ICU patients with Sputum Culture positive for Multi-drug resistant Acinetobacter baumannii,

12.

(2002) Looking for Risk Factors for the Acquisition of Antibiotic Resistance:A 21st-Century Approach,

13.

(2004) Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii:a case-control study,

14.

(1995) Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii,

15.

(1995) Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii:results of the case-control and molecular epidemiologic investigations,

16.

(1999) Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients,

17.

(1997) Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward:epidemiology and risk factors for acquisition,

18.

(1995) Nosocomial acquisition of multiresistant Acinetobacter baumannii:risk factors and prognosis,

19.

(2004) Spread of Novel Aminoglycoside Resistance Gene aac(6)-Iad among Acinetobacter Clinical Isolates in Japan,

20.

(2001) The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey,

21.

(1996) Antimicrobial-drug resistance,

22.

(2005) Pharmacokinetic /pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia,

23.

(2003) Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: A matched cohort study,

24.

(2001) Is ventilator-associated pneumonia an independent risk factor for death,

25.

(1993) Nosocomial pneumonia in ventilated patients:a cohort study evaluating attributable mortality and hospital stay,

26.

(2002) Epidemiology and outcomes of ventilator-associated pneumonia in a large US database,

27.

(2001) Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit:a prospective case-control study,

28.

(2005) What is ventilator-associated pneumonia and why is it important?,

29.

(2005) Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii:patient prognosis and risk-factors for colonisation and infection,

30.

(2005) Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria:the renaissance of an old antibiotic,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy